Anna Pia
安娜·皮亚
MD, PhD
Associate Professor of Endocrinology; Head, Calcium and Bone Metabolism Unit内分泌学副教授；钙与骨代谢科主任
👥Biography 个人简介
Anna Pia, MD, PhD is Associate Professor of Endocrinology at the University of Turin and head of the Calcium and Bone Metabolism Unit, with expertise in parathyroid carcinoma, CDC73/HRPT2 tumor suppressor genetics, and endocrine disruptor-related cancer risk. She has led European multicenter studies characterizing the clinical presentation, molecular basis, and treatment outcomes of parathyroid carcinoma—one of the rarest endocrine malignancies—and contributed to understanding how environmental endocrine-disrupting compounds influence parathyroid and thyroid tumorigenesis. Her work has informed European guidelines for parathyroid carcinoma management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CDC73 Tumor Suppressor in Parathyroid Carcinoma
Characterized CDC73/parafibromin loss as a key diagnostic and prognostic marker in parathyroid carcinoma, establishing immunohistochemical parafibromin staining as a standard adjunct in differentiating malignant from adenomatous parathyroid lesions.
European Registry for Parathyroid Carcinoma
Helped establish and analyze the European multicenter parathyroid carcinoma registry, providing the largest clinical dataset characterizing presentation, surgical outcomes, recurrence patterns, and systemic therapy responses in this rare malignancy.
Endocrine Disruptors and Thyroid/Parathyroid Cancer Risk
Investigated associations between environmental endocrine-disrupting chemicals (EDCs) and the development of thyroid nodules, differentiated thyroid cancer, and parathyroid adenoma, contributing epidemiological and mechanistic evidence to the EDC-cancer risk literature.
Representative Works 代表性著作
Parathyroid Carcinoma: Presentation, Management, and Outcomes in a European Multicenter Cohort
Journal of Clinical Endocrinology & Metabolism (2020)
Multicenter European analysis defining contemporary clinical features, surgical cure rates, and long-term outcomes in parathyroid carcinoma.
CDC73 Mutations and Parafibromin Expression as Diagnostic Markers of Parathyroid Malignancy
Endocrine-Related Cancer (2018)
Validated parafibromin immunostaining and CDC73 sequencing as complementary tools for diagnosing parathyroid carcinoma in challenging cases.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 安娜·皮亚 的研究动态
Follow Anna Pia's research updates
留下邮箱，当我们发布与 Anna Pia（University of Turin, A.O.U. Città della Salute e della Scienza）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment